Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2011

View Archived Issues

Phase I/II trials assess safety and immunogenicity of HIV vaccine F4/AS01

ATX-101 potentiates activity of chemotherapy in preclinical studies by disrupting cell cycle control

Phase I data support safety and tolerability of YH-4808 in healthy subjects

Vifor reports new hepcidin antagonists for treatment of anemia

Ambit Biosciences presents new tyrosine-protein kinase inhibitors

German researchers present novel agents for HIV

PET tracer [18F]-MK-3328 shows favorable pharmacological profile and promise in Alzheimer's disease

Kyowa Hakko Kirin begins phase III pegfilgrastim study in Japan

Novel activators of the K(Ca)2.3 channel synthesized by RaQualia researchers

Jasco Pharma and North Carolina Central University form research program

AFFiRiS' AD-02 Alzheimer's disease vaccine shows potential in phase I trial

Galapagos' GLPG-0187 enters phase Ib trial in patients with solid tumors

Oxford Vaccine Group receives grant from Action Medical Research to develop meningitis vaccine

Herceptin obtains additional approval in Japan for gastric cancer overexpressing HER2

Astellas files for Japanese approval of bixalomer for hyperphosphatemia

Janssen Pharma launches Stelara in Japan for psoriasis

Almirall launches Sativex in Spain for treatment of spasticity in MS

CTI gains rights to Chroma Therapeutics' antitumor drug tosedostat in the Americas

Collaboration established for research into beta-cell regeneration in diabetes

Phase III DEFEND-1 trial in type 1 diabetes does not meet primary endpoint

BioInvent advances phase II trial of cardiovascular drug candidate BI-204

Clinical evaluation of NVP-BKM-120 for treatment of endometrial and colorectal cancer under way

Phase I/II trial to assess safety/effectiveness of TRC-105 plus sorafenib in HCC is now recruiting

Preclinical anticancer activity supports entry of OCID-4681-S-01 in phase I trial in solid tumors

MRK-560 shows preference for PS-1-containing gamma-secretases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...